AbCellera Biologics (ABCL) Receivables (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Receivables came in at $39.2 million in Q1 2026, down 38.43% YoY from $63.6 million in Q1 2025, and down 32.82% on a QoQ basis from $58.3 million in Q4 2025.
AbCellera Biologics (ABCL) Receivables (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Receivables data on file, last reported at $39.2 million in Q1 2026.
- Quarterly Receivables fell 38.43% year-over-year to $39.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.2 million (down 38.43% YoY) and the FY2025 annual result came in at $58.3 million, up 73.41% from the prior year.
- Receivables declined to $39.2 million in Q1 2026, from $58.3 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $334.4 million in Q1 2022 to a low of $20.0 million in Q1 2023.
- A 5-year average of $64.9 million and a median of $39.2 million in 2026 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables soared 142.85% — and 2023, when it plunged 94.02%.
- Tracing ABCL's Receivables over 5 years: stood at $38.6 million in 2022, then decreased by 20.74% to $30.6 million in 2023, then grew by 9.89% to $33.6 million in 2024, then surged by 73.41% to $58.3 million in 2025, then plunged by 32.82% to $39.2 million in 2026.
- The last three Receivables figures came in at $39.2 million (Q1 2026), $58.3 million (Q4 2025), and $71.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 38.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.42 Mn |
| Mar 31, 2026 | 39.16 Mn |
| Dec 31, 2025 | 58.29 Mn |
| Sep 30, 2025 | 71.25 Mn |
| Jun 30, 2025 | 70.01 Mn |
| Mar 31, 2025 | 63.61 Mn |
| Dec 31, 2024 | 33.62 Mn |
| Sep 30, 2024 | 31.37 Mn |
| Jun 30, 2024 | 36.14 Mn |
| Mar 31, 2024 | 34.42 Mn |
| Dec 31, 2023 | 30.59 Mn |
| Sep 30, 2023 | 37.45 Mn |
| Jun 30, 2023 | 45.68 Mn |
| Mar 31, 2023 | 20.00 Mn |
| Dec 31, 2022 | 38.59 Mn |
| Sep 30, 2022 | 105.96 Mn |
| Jun 30, 2022 | 52.80 Mn |
| Mar 31, 2022 | 334.40 Mn |
| Dec 31, 2021 | 160.58 Mn |
| Sep 30, 2021 | 43.63 Mn |